Year |
Award | Recipient |
|---|---|---|
| 2022 |
Allen Lichter Visionary Leader Award |
Richard L. Schilsky, FSCT, FASCO, FACP, MD |
| 2021 |
Allen Lichter Visionary Leader Award |
Daniel F. Hayes, MD, FASCO, FACP |
| 2020 |
Allen Lichter Visionary Leader Award |
Hyman B. Muss, MD, FASCO |
| 2019 |
Allen Lichter Visionary Leader Award |
Ian Tannock, MD, PhD, FASCO |
| 2018 |
Allen Lichter Visionary Leader Award |
Nancy E. Davidson, MD, FASCO |
| 2017 |
Allen Lichter Visionary Leader Award |
Patrick J. Loehrer, FASCO, MD, FACP |
ASCO Family of Sites
ASCOconnection.org features blogs from members, the online version of the membership magazine, a discussion area, working groups, and links to the Membership Directory, Career Center, and Volunteer Portal.
ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members and oncology health care providers.
ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe.
ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care.
Stay updated on the latest oncology has to offer with ASCO Education—your online, on-demand resource for timely information, real-world application, and practice-changing care.
A cutting-edge health information technology platform, CancerLinQ® enables practitioners to learn from individual patients. By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care.
Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions.
Conquer Cancer, the ASCO Foundation, raises funds to support the world's leading researchers who are improving treatments and discovering cures for every cancer, every patient, everywhere.
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant.
The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and members.